A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Aulos Bioscience, Inc.
Exelixis
Neonc Technologies, Inc.
ImmunityBio, Inc.
University of Pittsburgh
Mayo Clinic
BicycleTx Limited
University of Pittsburgh
Nanobiotix
Incyte Corporation
Bristol-Myers Squibb
Molecular Templates, Inc.
Rutgers, The State University of New Jersey
Tempest Therapeutics
H. Lee Moffitt Cancer Center and Research Institute
Nektar Therapeutics
Incyte Corporation
Genocea Biosciences, Inc.
Celldex Therapeutics